Coleman Amanda E, Brown Scott A, Traas Anne M, Bryson Lawrence, Zimmering Tanja, Zimmerman Alicia
Department of Small Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia.
Department of Physiology and Pharmacology, University of Georgia College of Veterinary Medicine, Athens, Georgia.
J Vet Intern Med. 2019 Mar;33(2):478-488. doi: 10.1111/jvim.15429. Epub 2019 Mar 9.
Information regarding the efficacy of telmisartan for feline systemic arterial hypertension is limited.
To evaluate the safety and efficacy of PO administered telmisartan solution in hypertensive cats.
Client-owned cats with indirect systolic arterial blood pressure (SBP) of 160-200 mm Hg, based on multiple measurements.
This multicenter trial consisted a 28-day, prospective, randomized, double-blind, placebo-controlled, parallel group, efficacy phase and a 154-day extended-use telmisartan phase. Hypertensive cats were randomly assigned to receive 1.5 mg telmisartan/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h, or equivalent volume of placebo. Systolic blood pressure was measured on days 0, 14, and 28. Change in SBP compared to baseline was calculated for days 14 and 28. Telmisartan efficacy was defined as significant decrease in SBP at day 14 compared to placebo and a clinically relevant (>20 mm Hg) decrease in SBP at day 28.
Two-hundred twenty-one cats were included. On day 14, least squares mean (95% confidence interval) SBP decrease was significantly larger in telmisartan-treated (-23.3 mm Hg [-28.2 to -18.3]) versus placebo-treated (-7.5 mm Hg [-13.6 to -1.5]) cats (P = .0005). On day 28, telmisartan treatment resulted in a clinically relevant SBP decrease (-23.9 mm Hg [-27.8 to -20.0]), whereas placebo did not (-11.6 mm Hg [-17.4 to -5.9 mm Hg]). The decrease in SBP persisted over the 6-month trial in telmisartan-treated cats.
Telmisartan significantly decreased SBP to a clinically relevant extent and was well tolerated in hypertensive cats.
关于替米沙坦对猫全身性动脉高血压疗效的信息有限。
评估口服替米沙坦溶液对高血压猫的安全性和疗效。
基于多次测量，收缩期动脉血压（SBP）间接测量值为160 - 200 mmHg的客户拥有的猫。
这项多中心试验包括一个为期28天的前瞻性、随机、双盲、安慰剂对照、平行组疗效阶段和一个为期154天的替米沙坦延长使用阶段。高血压猫被随机分配接受1.5 mg替米沙坦/千克口服，每12小时一次，共14天，然后2 mg替米沙坦/千克口服，每24小时一次，或等量的安慰剂。在第0、14和28天测量收缩压。计算第14天和28天与基线相比SBP的变化。替米沙坦疗效定义为与安慰剂相比，第14天SBP显著降低，且第28天SBP有临床相关的（>20 mmHg）降低。
纳入221只猫。在第14天，替米沙坦治疗组（-23.3 mmHg [-28.2至-18.3]）的最小二乘均值（95%置信区间）SBP降低显著大于安慰剂治疗组（-7.5 mmHg [-13.6至-1.5]）的猫（P = .0005）。在第28天，替米沙坦治疗导致临床相关的SBP降低（-23.9 mmHg [-27.8至-20.0]），而安慰剂组没有（-1)1.6 mmHg [-17.4至-5.9 mmHg]）。在替米沙坦治疗的猫中，SBP降低在6个月的试验中持续存在。
替米沙坦可将SBP显著降低至临床相关程度，且高血压猫耐受性良好。
